Sana Biotechnology Q3 2026 swings to net profit of $20.4 million
SANA•Sana Biotechnology reported third-quarter 2026 net income of $20.4 million, compared with a $42.2 million year-earlier loss. Non-cash revaluation gains totaled $63.4 million; cash and marketable securities were $121.7 million at September 30, with runway expected into mid-2027.
1. Quarterly results
Sana Biotechnology swung to third-quarter 2026 net income of $20.4 million from a loss of $42.2 million a year earlier. Non-cash gains from revaluing success-payment liabilities and contingent consideration totaled $63.4 million, primarily reflecting an amendment to the Cobalt acquisition agreement.
2. Cash and clinical plans
Cash, cash equivalents and marketable securities totaled $121.7 million at September 30, with the company expecting its cash runway to extend into mid-2027. Clinical studies of diabetes therapy SC451 and lymphoma treatment SG293 are expected to begin later in 2026 and in the first quarter of 2027, respectively.
